Review Papers Claim by Claim

• Multi-pronged evidence: proteomics → endogenous co-IP → purified reconstitution → cellular loss/gain-of-function assays (cross-species) supports a direct enzymatic role.
• Catalytic requirement is tested (C298A mutant and truncation variant), strengthening causality between USP15 enzymatic activity and CARD9 deubiquitination/function.
• Linkage to prior TRIM62 work (same site/linkage) and to structural mechanisms around Lys125 increases mechanistic coherence across studies (TRIM62–CARD9 (2015), CARD9 structure (2019)).

• Limited in vivo data: no USP15 knockout mouse infection or inflammation models presented to show physiological relevance (e.g., fungal challenge or colitis). This is the main generalizability gap.
• Overreliance on overexpression or engineered systems (HEK293T co-IPs, Dectin-1–overexpressing THP-1 reporter lines) can misrepresent stoichiometry or off-target interactions.
• Small sample sizes in some assays (n=3 mice in BMDC ELISA, small pools of THP-1 clones) reduce statistical power; raw numerical data and full replicate blots are not publicly deposited in the paper, limiting reproducibility checks.
• Specificity vs other DUBs: USP15 is broadly expressed and has many substrates; redundancy with other DUBs was not surveyed—possible compensation or off-target effects not excluded (e.g., USP15 also targets TRIM25, MDM2 etc. in other contexts USP15 pleiotropy (ImmunoHorizons 2020)).
• No ubiquitin linkage mapping in the current paper: the authors rely on prior TRIM62 K27-linkage identification; while in vitro removal by USP15 is shown, explicit demonstration that USP15 removes K27-linked chains on K125 in-cell (e.g., linkage-specific ubiquitin mutants or mass-spectrometric ubiquitin remnant mapping) would strengthen the claim.

Novelty: 9 — Identifying a DUB opposing a previously identified activating E3 (TRIM62) at the same pathway provides high novelty in ubiquitin-mediated regulation of innate immunity (TRIM62 context (2015)).

Quality: 8 — Robust biochemical and cellular work, appropriate mutants, cross-species cell assays; lack of in vivo USP15 data and limited raw-data deposition deducts points.

Generality: 7 — Work directly applies to CLR–CARD9 signaling and likely generalizable to other CBM-related regulation but requires tissue/in vivo validation.

Usefulness: 8 — Suggests potential nodes (USP15–CARD9) for modulating antifungal or inflammatory responses; translational potential contingent on in vivo studies.

Reproducibility: 7 — Methods are standard (IP, in vitro reconstitution, shRNA/CRISPR); absence of deposited raw MS/gel/source-data and small n reduce reproducibility score.

Explanatory depth: 8 — Combines biochemical, cellular, and structural context (via external structural literature) to provide a plausible mechanistic model.

Novel hypothesis 1: Acute inflammatory states that upregulate USP15 in myeloid cells act as a negative feedback brake on antifungal CLR signaling to limit tissue-damaging cytokine production; prediction: LPS or type I IFN will induce USP15 expression and reduce subsequent CLR responses in BMDCs.

Novel hypothesis 2: Certain CARD9 disease-associated variants (e.g., S12N or C-terminal truncations) alter USP15 binding and thus change sensitivity to deubiquitination; prediction: co-IP and activity assays will show variant-specific differences in USP15 binding and deubiquitination kinetics.

Experiment (concise): Use primary human monocyte-derived DCs from healthy donors, transduce with CARD9 WT or S12N or D11 constructs at near-physiological expression, measure endogenous USP15–CARD9 co-IP, K-ε-GG mapping at K125, and WGP-induced TNF-α in presence/absence of USP15 siRNA — this will test both binding specificity and physiological outcome.